Imbruvica (ibrutinib) is a Bruton's tyrosine kinase (BTK) inhibitor approved to treat Mantle Cell Lymphoma, Chronic Lymphocytic Leukemia, Waldenstrom's Macroglobulinemia, Relapsed/Refractory Marginal Zone Lymphoma and Chronic Graft-Versus-Host-Disease and currently being evaluated in multiple types of cancer and for other serious diseases.
Type of MoleculeSmall Molecule
Product TypeNew Indication
|Potential Indication||Region||Phase (1, 2, 3, Submitted)|
|Mantle Cell Lymphoma||n/a||